Clinical Trials Browser

Phase 3 × Panobinostat × Other hematologic neoplasm × Clear all

NCT04326764 2023-02-16

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Phase 3 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute